AARTI DRUGS LIMITED

Haaretz.com provides breaking news, analyses, and opinions on Israel, the Middle East, and the Jewish World.

HFCL partners with GA-ASI for UAS sub-systems, Dreamfolks Services addresses disruption, Sterling and Wilson Renewable Energy CFO resigns, Ugro Capital postpones board meeting, Aster DM Healthcare leases land for new hospital, Vodafone Idea signs $3.6 billion network deal, ONGC Videsh secures gas deal in Azerbaijan, USFDA inspects Glenmark Pharmaceuticals with no observations, Ramco Cements expands capacity, BHEL awarded NTPC contract, Reliance Industries extends call money payment deadline, USFDA inspects Aarti Drugs with Form 483 observations, Tata Steel commissions India’s largest blast furnace, Avalon Technologies CFO resigns, USFDA inspects Dr Reddy’s Laboratories with zero observations, HDFC Bank approves HDB Financial Services IPO, Bharat Forge enters renewable energy agreement, Signature Global CFO resigns, JM Financial reappoints and appoints MDs, Adani Total Gas secures international financing, Godfrey Phillips India considers bonus shares, Mankind Pharma approves fund raising, Vanguard Group Inc buys stakes in various companies.

Biocon received 3 observations from USFDA after inspection of Bengaluru API facility. Aarti Drugs received 7 observations from USFDA after inspection of Tarapur API facility. Glenmark Pharmaceuticals received zero observations from USFDA after inspection of Aurangabad formulation facility.